Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381125526> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4381125526 abstract "<h3>Introduction</h3> Tofacitinib is a pan-Janus Kinase inhibitor which is effective for induction and maintenance of remission in moderate to severely active ulcerative colitis (UC). The safety and efficacy of tofacitinib in UC patients has been demonstrated in trials. Long term experience is important in establishing the role of the drug in routine practice, but is currently limited. <h3>Methods</h3> Patients starting tofacitinib for moderate to severely active UC, refractory to anti-TNF, agents at a single tertiary centre between 2018 and 2020 (to ensure follow-up ≥ 2 years) were retrospectively evaluated until the study end point, January 2023. Disease activity was calculated using the Simple Clinical Colitis Activity Index (SCCAI). Response was defined at week 8 and 26 as a reduction in SCCAI of ≥3. Treatment persistence with tofacitinib was defined as time from treatment initiation to discontinuation (months) and censored at treatment discontinuation. Kaplan Meier methodology was used to estimate the median drug persistence (months). <h3>Results</h3> 39 patients, median age 45 (IQR 32–62yrs), 56% were male, were included. Median baseline SCCAI was 8 (IQR 7–10). Median CRP 5mg/L (IQR 0.8–11) and Faecal Calprotectin (FCP) 588mg/kg (IQR 108–1664). All patients were exposed to at least 1 anti-TNF agent and 77% (30/39) to vedolizumab. Median follow-up 37 (IQR 34–46) months. Response was observed in 74% (29/39) at week 8 (median SCCAI -5 (IQR -3 to -8) (p<0.0001 95% CI 4.53–6.80) and 64% (25/39) at week 26 (median SCCAI -7 IQR -5 to -8) p<0.0001 (95%CI 5.31–7.47). Treatment persistence was 65% (24/39) at 12 months and 44% (17/39) at the end of the study (figure 1), of these 29% (5/17) were on escalated dosing 10mg BD. Adverse events requiring drug withdrawal occurred in 15% (6/39; flu like symptoms (4), saddle pulmonary embolus (1), myocardial infarction (1). <h3>Conclusion</h3> Tofacitinib is effective in routine clinical practice in anti-TNF refractory UC, with good treatment persistence in long-term use, particularly in those who maintain response at 12 months. Limitations of our study include the small sample size and retrospective nature." @default.
- W4381125526 created "2023-06-19" @default.
- W4381125526 creator A5022771866 @default.
- W4381125526 creator A5025662872 @default.
- W4381125526 creator A5035249747 @default.
- W4381125526 creator A5062779449 @default.
- W4381125526 creator A5067370520 @default.
- W4381125526 creator A5068737747 @default.
- W4381125526 creator A5076761116 @default.
- W4381125526 creator A5076781099 @default.
- W4381125526 creator A5088625283 @default.
- W4381125526 creator A5091774834 @default.
- W4381125526 date "2023-06-01" @default.
- W4381125526 modified "2023-09-27" @default.
- W4381125526 title "P103 Long term treatment with tofacitinib for ulcerative colitis refractory to anti-tumour necrosis factor agents: real-world experience from a single centre" @default.
- W4381125526 doi "https://doi.org/10.1136/gutjnl-2023-bsg.175" @default.
- W4381125526 hasPublicationYear "2023" @default.
- W4381125526 type Work @default.
- W4381125526 citedByCount "0" @default.
- W4381125526 crossrefType "proceedings-article" @default.
- W4381125526 hasAuthorship W4381125526A5022771866 @default.
- W4381125526 hasAuthorship W4381125526A5025662872 @default.
- W4381125526 hasAuthorship W4381125526A5035249747 @default.
- W4381125526 hasAuthorship W4381125526A5062779449 @default.
- W4381125526 hasAuthorship W4381125526A5067370520 @default.
- W4381125526 hasAuthorship W4381125526A5068737747 @default.
- W4381125526 hasAuthorship W4381125526A5076761116 @default.
- W4381125526 hasAuthorship W4381125526A5076781099 @default.
- W4381125526 hasAuthorship W4381125526A5088625283 @default.
- W4381125526 hasAuthorship W4381125526A5091774834 @default.
- W4381125526 hasConcept C121332964 @default.
- W4381125526 hasConcept C126322002 @default.
- W4381125526 hasConcept C141071460 @default.
- W4381125526 hasConcept C142424586 @default.
- W4381125526 hasConcept C17991360 @default.
- W4381125526 hasConcept C2776207728 @default.
- W4381125526 hasConcept C2777138892 @default.
- W4381125526 hasConcept C2777575956 @default.
- W4381125526 hasConcept C2778260677 @default.
- W4381125526 hasConcept C2778715236 @default.
- W4381125526 hasConcept C2778886723 @default.
- W4381125526 hasConcept C2779134260 @default.
- W4381125526 hasConcept C2780479503 @default.
- W4381125526 hasConcept C71924100 @default.
- W4381125526 hasConcept C87355193 @default.
- W4381125526 hasConcept C90924648 @default.
- W4381125526 hasConceptScore W4381125526C121332964 @default.
- W4381125526 hasConceptScore W4381125526C126322002 @default.
- W4381125526 hasConceptScore W4381125526C141071460 @default.
- W4381125526 hasConceptScore W4381125526C142424586 @default.
- W4381125526 hasConceptScore W4381125526C17991360 @default.
- W4381125526 hasConceptScore W4381125526C2776207728 @default.
- W4381125526 hasConceptScore W4381125526C2777138892 @default.
- W4381125526 hasConceptScore W4381125526C2777575956 @default.
- W4381125526 hasConceptScore W4381125526C2778260677 @default.
- W4381125526 hasConceptScore W4381125526C2778715236 @default.
- W4381125526 hasConceptScore W4381125526C2778886723 @default.
- W4381125526 hasConceptScore W4381125526C2779134260 @default.
- W4381125526 hasConceptScore W4381125526C2780479503 @default.
- W4381125526 hasConceptScore W4381125526C71924100 @default.
- W4381125526 hasConceptScore W4381125526C87355193 @default.
- W4381125526 hasConceptScore W4381125526C90924648 @default.
- W4381125526 hasLocation W43811255261 @default.
- W4381125526 hasOpenAccess W4381125526 @default.
- W4381125526 hasPrimaryLocation W43811255261 @default.
- W4381125526 hasRelatedWork W2006826205 @default.
- W4381125526 hasRelatedWork W2042655884 @default.
- W4381125526 hasRelatedWork W2152399325 @default.
- W4381125526 hasRelatedWork W3147462706 @default.
- W4381125526 hasRelatedWork W3195828941 @default.
- W4381125526 hasRelatedWork W3210743084 @default.
- W4381125526 hasRelatedWork W4206728214 @default.
- W4381125526 hasRelatedWork W4213385218 @default.
- W4381125526 hasRelatedWork W4362586872 @default.
- W4381125526 hasRelatedWork W4383388333 @default.
- W4381125526 isParatext "false" @default.
- W4381125526 isRetracted "false" @default.
- W4381125526 workType "article" @default.